H. Lundbeck A/S (HLBBF)
7.29
0.00 (0.00%)
USD |
OTCM |
Jun 10, 16:00
H. Lundbeck Enterprise Value : 8.616B for June 10, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 10, 2026 | 8.616B |
| June 09, 2026 | 8.616B |
| June 08, 2026 | 8.616B |
| June 05, 2026 | 8.616B |
| June 04, 2026 | 8.616B |
| June 03, 2026 | 8.616B |
| June 02, 2026 | 8.616B |
| June 01, 2026 | 8.616B |
| May 29, 2026 | 8.616B |
| May 28, 2026 | 8.616B |
| May 27, 2026 | 7.882B |
| May 26, 2026 | 7.882B |
| May 22, 2026 | 7.882B |
| May 21, 2026 | 8.487B |
| May 20, 2026 | 8.487B |
| May 19, 2026 | 8.487B |
| May 18, 2026 | 8.487B |
| May 15, 2026 | 8.487B |
| May 14, 2026 | 8.487B |
| May 13, 2026 | 8.487B |
| May 12, 2026 | 8.487B |
| May 11, 2026 | 8.487B |
| May 08, 2026 | 8.487B |
| May 07, 2026 | 8.487B |
| May 06, 2026 | 8.487B |
| Date | Value |
|---|---|
| May 05, 2026 | 8.487B |
| May 04, 2026 | 7.981B |
| May 01, 2026 | 8.229B |
| April 30, 2026 | 8.229B |
| April 29, 2026 | 8.229B |
| April 28, 2026 | 8.229B |
| April 27, 2026 | 8.229B |
| April 24, 2026 | 8.229B |
| April 23, 2026 | 7.237B |
| April 22, 2026 | 7.237B |
| April 21, 2026 | 7.237B |
| April 20, 2026 | 7.237B |
| April 17, 2026 | 7.237B |
| April 16, 2026 | 7.237B |
| April 15, 2026 | 7.237B |
| April 14, 2026 | 7.237B |
| April 13, 2026 | 7.237B |
| April 10, 2026 | 7.237B |
| April 09, 2026 | 7.237B |
| April 08, 2026 | 7.237B |
| April 07, 2026 | 7.237B |
| April 06, 2026 | 7.237B |
| April 02, 2026 | 7.237B |
| April 01, 2026 | 7.237B |
| March 31, 2026 | 7.510B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Novo Nordisk A/S | 163.47B |
| ALK-Abello A/S | 8.442B |
| AstraZeneca PLC | 581.37B |
| ANI Pharmaceuticals, Inc. | 2.161B |
| Corcept Therapeutics, Inc. | 8.056B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 259.64M |
| Revenue (Quarterly) | 1.100B |
| Total Expenses (Quarterly) | 840.47M |
| EPS Diluted (Quarterly) | 0.2616 |
| Gross Profit Margin (Quarterly) | 80.03% |
| Profit Margin (Quarterly) | 23.60% |
| Earnings Yield | 7.95% |
| Operating Earnings Yield | 14.96% |
| Normalized Earnings Yield | 9.566 |